

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): **August 11, 2021**

**Heat Biologics, Inc.**

*(Exact name of registrant as specified in charter)*

**Delaware**

*(State or other jurisdiction of incorporation)*

**001-35994**

*(Commission File Number)*

**26-2844103**

*(IRS Employer Identification No.)*

**627 Davis Drive, Suite 400  
Morrisville, North Carolina 27560**

*(Address of principal executive offices and zip code)*

**(919) 240-7133**

*(Registrant's telephone number including area code)*

**N/A**

*(Former Name and Former Address)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                        | Trading Symbol(s) | Name of each exchange on which registered                   |
|--|-------------------|---|
| Common Stock, \$0.0002 par value per share | HTBX              | The Nasdaq Stock Market, LLC<br>(The Nasdaq Capital Market) |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02 Results of Operations and Financial Condition.**

On August 11, 2021, Heat Biologics, Inc., a Delaware corporation (the “Registrant”), issued the attached press release that included financial information for its quarter ended June 30, 2021. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 2.02 and in the press release is being furnished to the Securities and Exchange Commission (the “Commission”) and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

| <b>Exhibit<br/>Number</b>   | <b>Description</b>   |
|-----------------------------|--|
| <a href="#"><u>99.1</u></a> | <a href="#"><u>Press Release issued by Heat Biologics, Inc. August 11, 2021.</u></a>     |
| 104                         | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 11, 2021

HEAT BIOLOGICS, INC.

By: /s/ Jeffrey Wolf  
Name: Jeffrey Wolf  
Title: Chairman, President and  
Chief Executive Officer

---



## Heat Biologics Provides Second Quarter 2021 Business Update

**Durham, NC – August 11, 2021 – Heat Biologics, Inc. (“Heat”)** (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided financial, clinical and operational updates for the second quarter ended June 30, 2021.

Jeff Wolf, Chief Executive Officer of Heat, commented, “This quarter we achieved several meaningful clinical, research and business milestones. First, we presented favorable survival data of HS-110 in previously treated non-small cell lung cancer (NSCLC) patients at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on these results, we believe HS-110, in combination with a checkpoint inhibitor (CPI), holds significant potential to improve survival benefit for patients with non-small cell lung cancer. We are continuing to evaluate possible Phase 3 registration pathways with the FDA and potential partners. At the same time, we are exploring a variety of paths forward related to our infectious disease efforts. We look forward to providing further near-term updates.”

“This quarter we also announced the groundbreaking for our biomanufacturing/bioanalytic facility in San Antonio, TX and the expansion of our current research and development (R&D) facilities at our corporate headquarters in Morrisville, NC. This expansion will support enhanced R&D capabilities including in-house synthesis and production of antibodies and other drugs/reagents, as well as an expanded vivarium for onsite pre-clinical studies. We believe that this expansion will allow us to accelerate R&D timelines and generate cost savings on research and development by bringing more of our development activities in-house.”

“Moreover, we have maintained a strong balance sheet with approximately \$122.5 million of cash, cash equivalents and short-term investments which should allow us to augment our clinical programs as well as enhance and expand our therapeutic pipeline.”

### Second Quarter 2021 Financial Results

- Recognized \$0.5 million of grant revenue for qualified expenditures under the CPRIT grant compared to \$0.6 million for the quarter ended June 30, 2020. The decrease in grant revenue in the current-year period primarily reflects the expected timing of completion of deliveries under the current phase of the contracts. As of June 30, 2021, we had a grant receivable balance of \$0.4 million for CPRIT proceeds not yet received but for which the costs had been incurred or the conditions of the award had been met. We continue our efforts to secure future non-dilutive grant funding to subsidize ongoing research and development costs.
  - Research and development expense was \$4.2 million and \$2.8 million for the three months ended June 30, 2021 and 2020, respectively.
  - General and administrative expense was \$2.9 million and \$1.8 million for the three months ended June 30, 2021 and 2020. The increase was primarily due to an increase in stock-based compensation expense.
  - Net loss attributable to Heat Biologics was approximately \$6.5 million, or (\$0.26) per basic and diluted share for the quarter ended June 30, 2021 compared to a net loss of approximately of \$4.5 million, or (\$0.35) per basic and diluted share for the quarter ended June 30, 2020.
  - As of June 30, 2021, the Company had approximately \$122.5 million in cash, cash equivalents and short investments.
-

## **About Heat Biologics, Inc.**

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, various infectious disease programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

For more information, please visit: [www.heatbio.com](http://www.heatbio.com), and also follow us on Twitter.

## **Forward Looking Statement**

*This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements regarding the potential of HS-110, in combination with a checkpoint inhibitor (CPI), to improve survival benefit for patients with non-small cell lung cancer; providing further near-term HS-110 updates, the expansion of Heat's current research and development (R&D) facilities at its corporate headquarters in Morrisville, North Carolina allowing Heat to accelerate R&D timelines and generate cost savings on research and development by bringing more of our development activities in-house and Heat's balance sheet allowing it to augment its clinical programs as well as enhance and expand its therapeutic pipeline. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of HS-110, in combination with a checkpoint inhibitor (CPI), holds significant potential to improve survival benefit for patients with non-small cell lung cancer, the ability of Heat's vaccine platform to provide prevention and treatment of cancer and infectious diseases, such as COVID-19, Heat's ability to provide further near-term updates, Heat's ability to accelerate R&D timelines and generate cost savings on research and development by bringing more of its development activities in-house, Heat's ability to augment its clinical programs and enhance and expand its therapeutic pipeline, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, especially in light of COVID-19, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities and its cash and short-term investments providing significant runway to fund Heat's current clinical programs and further expand Heat's therapeutic portfolio, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's annual report on Form 10-K for the year ended December 31, 2020 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.*

## **Media and Investor Relations Contact**

David Waldman  
+1 919 289 4017  
[investorrelations@heatbio.com](mailto:investorrelations@heatbio.com)

(tables follow)

---

**HEAT BIOLOGICS, INC.**  
**Consolidated Balance Sheets**

|  | June 30,<br>2021<br>(unaudited) | December 31,<br>2020  |
|--|---------------------------------|-----------------------|
| <b>Current Assets</b>  |                                 |                       |
| Cash and cash equivalents  | \$ 21,567,287                   | \$ 10,931,890         |
| Short-term investments   | 100,964,986                     | 100,842,438           |
| Accounts receivable  | 102,593                         | 177,239               |
| Prepaid expenses and other current assets  | 2,124,419                       | 1,842,620             |
| <b>Total Current Assets</b>  | <u>124,759,285</u>              | <u>113,794,187</u>    |
| <b>Property and Equipment, net</b>   | <u>4,146,111</u>                | <u>676,262</u>        |
| <b>Other Assets</b>  |                                 |                       |
| In-process R&D   | 5,866,000                       | 5,866,000             |
| Goodwill   | 1,452,338                       | 1,452,338             |
| Grant receivable   | 368,465                         | —                     |
| Operating lease right-of-use asset   | 1,857,309                       | 2,035,882             |
| Finance lease right-of-use asset   | 187,744                         | 247,194               |
| Deposits   | 152,267                         | 122,779               |
| <b>Total Other Assets</b>  | <u>9,884,123</u>                | <u>9,724,193</u>      |
| <b>Total Assets</b>  | <u>\$ 138,789,519</u>           | <u>\$ 124,194,642</u> |
| <b>Liabilities and Stockholders' Equity</b>  |                                 |                       |
| <b>Current Liabilities</b>   |                                 |                       |
| Accounts payable   | \$ 1,180,965                    | \$ 1,051,764          |
| Deferred revenue, current portion  | —                               | 603,717               |
| Operating lease liability, current portion   | 293,226                         | 278,753               |
| Finance lease liability, current portion   | 111,411                         | 108,127               |
| Accrued expenses and other liabilities   | 1,766,311                       | 1,614,534             |
| <b>Total Current Liabilities</b>   | <u>3,351,913</u>                | <u>3,656,895</u>      |
| <b>Long Term Liabilities</b>   |                                 |                       |
| Other long-term liabilities  | 48,949                          | 36,243                |
| Derivative warrant liability   | 37,802                          | 33,779                |
| Deferred tax liability   | 361,911                         | 361,911               |
| Deferred revenue, net of current portion   | 237,500                         | 237,500               |
| Operating lease liability, net of current portion  | 1,151,886                       | 1,301,636             |
| Financing lease liability, net of current portion  | 103,700                         | 160,240               |
| Contingent consideration, net of current portion   | 2,336,626                       | 2,250,844             |
| Contingent consideration, related party - net of current portion   | 686,889                         | 661,671               |
| <b>Total Liabilities</b>   | <u>8,317,176</u>                | <u>8,700,719</u>      |
| <b>Stockholders' Equity</b>  |                                 |                       |
| Common stock, \$.0002 par value; 250,000,000 and 250,000,000 shares authorized, 25,137,502 and 22,592,500 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively | 5,027                           | 4,519                 |
| Additional paid-in capital   | 276,225,048                     | 247,048,349           |
| Accumulated deficit  | (144,722,860)                   | (130,647,485)         |
| Accumulated other comprehensive loss   | (121,127)                       | (166,056)             |
| <b>Total Stockholders' Equity - Heat Biologics, Inc.</b>   | <u>131,386,088</u>              | <u>116,239,327</u>    |
| <b>Non-Controlling Interest</b>  | <u>(913,745)</u>                | <u>(745,404)</u>      |
| <b>Total Stockholders' Equity</b>  | <u>130,472,343</u>              | <u>115,493,923</u>    |
| <b>Total Liabilities and Stockholders' Equity</b>  | <u>\$ 138,789,519</u>           | <u>\$ 124,194,642</u> |

**HEAT BIOLOGICS INC.**  
**Consolidated Statements of Operations and Comprehensive Loss**  
**(unaudited)**

|   | Three Months Ended<br>June 30, |                | Six Months Ended<br>June 30, |                 |
|---|--------------------------------|----------------|------------------------------|-----------------|
|   | 2021                           | 2020           | 2021                         | 2020            |
| <b>Revenue:</b>   |                                |                |                              |                 |
| Grant and contract revenue                                    | \$ 459,494                     | \$ 593,165     | \$ 998,139                   | \$ 1,495,045    |
| <b>Operating expenses:</b>                                    |                                |                |                              |                 |
| Research and development                                      | 4,216,294                      | 2,790,797      | 7,622,542                    | 5,573,303       |
| General and administrative                                    | 2,853,265                      | 1,801,674      | 7,620,910                    | 5,072,222       |
| Change in fair value of contingent consideration              | 105,000                        | 843,000        | 111,000                      | 816,000         |
| Total operating expenses                                      | 7,174,559                      | 5,435,471      | 15,354,452                   | 11,461,525      |
| Loss from operations  | (6,715,065)                    | (4,842,306)    | (14,356,313)                 | (9,966,480)     |
| Change in fair value of warrant liability                     | 4,679                          | (24,363)       | (4,023)                      | (1,002,073)     |
| Investor relations expense                                    | —                              | —              | —                            | (66,767)        |
| Interest income   | 176,798                        | 56,080         | 371,963                      | 108,790         |
| Other (expense) income, net                                   | (86,988)                       | 273,771        | (255,343)                    | 16,292          |
| Total non-operating income (loss)                             | 94,489                         | 305,488        | 112,597                      | (943,758)       |
| Net loss before income taxes                                  | (6,620,576)                    | (4,536,818)    | (14,243,716)                 | (10,910,238)    |
| Income tax expense  | —                              | —              | —                            | —               |
| Net loss  | (6,620,576)                    | (4,536,818)    | (14,243,716)                 | (10,910,238)    |
| Net loss - non-controlling interest                           | (77,379)                       | (82,388)       | (168,341)                    | (163,702)       |
| Net loss attributable to Heat Biologics, Inc.                 | \$ (6,543,197)                 | \$ (4,454,430) | \$ (14,075,375)              | \$ (10,746,536) |
| Net loss per share, basic and diluted                         | \$ (0.26)                      | \$ (0.35)      | \$ (0.57)                    | \$ (1.04)       |
| Weighted-average common shares outstanding, basic and diluted | 25,137,466                     | 12,561,549     | 24,671,281                   | 10,372,352      |
| <b>Comprehensive loss:</b>                                    |                                |                |                              |                 |
| Net loss  | \$ (6,620,576)                 | \$ (4,536,818) | \$ (14,243,716)              | \$ (10,910,238) |
| Unrealized gain (loss) on foreign currency translation        | 26,661                         | (179,510)      | 44,929                       | 39,294          |
| Total comprehensive loss                                      | (6,593,915)                    | (4,716,328)    | (14,198,787)                 | (10,870,944)    |
| Comprehensive loss attributable to non-controlling interest   | (77,379)                       | (82,388)       | (168,341)                    | (163,702)       |
| Comprehensive loss - Heat Biologics, Inc.                     | \$ (6,516,536)                 | \$ (4,633,940) | \$ (14,030,446)              | \$ (10,707,242) |